Developing a universal influenza vaccine to improve immunity
Synthetic multi-component influenza vaccines to elicit broad immunity
This study is working on a new flu vaccine that aims to protect people, especially older adults and those with weakened immune systems, from different strains of the virus by using a mix of ingredients to boost their immune response.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-11002304 on NIH RePORTER |
What this research studies
This research aims to create a universal influenza vaccine that can provide better protection against various strains of the virus, especially for vulnerable populations like the elderly and immunocompromised individuals. The approach involves synthesizing a vaccine that combines multiple components, including specific immune targets and an adjuvant to enhance the immune response. By focusing on broadly cross-reactive elements, the goal is to elicit strong immune responses that can protect against diverse influenza A virus infections. The research builds on previous findings that demonstrated the effectiveness of multi-component vaccines in animal models.
Who could benefit from this research
Good fit: Ideal candidates for this research include elderly individuals, infants, and those with compromised immune systems who are at higher risk for influenza complications.
Not a fit: Patients who are not at risk for influenza complications or those who have already received effective seasonal vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective influenza vaccine that offers broader protection and reduces the disease burden associated with seasonal and pandemic influenza.
How similar studies have performed: Previous research has shown promise in developing multi-component vaccines, indicating that this approach could be a viable strategy for improving influenza vaccination.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Boons, Geert-Jan — University of Georgia
- Study coordinator: Boons, Geert-Jan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.